Loading...
Our Company2018-07-03T12:45:20+00:00

Cancer is a complex disease, and for therapies to be maximally effective and tolerable, they must distinguish between normal and cancerous cells. Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells, Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting the potential of this type of agent.

Our People

Dr. Allen (Alexander) Krantz

Dr. Allen (Alexander) Krantz

Founder, CSO and COO

Allen Krantz has had an extensive career in academia and industry. From 1968 to 1980, he was a member of the Faculty of Chemistry at Stony Brook University, holding appointments in both the Department of Chemistry, and the Department of Pharmacological Sciences in the University’s Medical School. From 1981 to 1994, Dr. Krantz was Director, and then Vice-President of Research at Syntex Research Canada and held Adjunct Professorships during this period at the Universities of Toronto and Guelph while holding the title of Distinguished Scientist at the Corporation… From 1994 to 1997, Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique of the European office in France during the same period. Dr. Krantz was responsible for transforming the company’s program to a practical focal point on human serum albumin as a carrier of drugs. He is also a Founder, and served as the inaugural President of Pharmena North America Incorporated, a privately held, biotechnology company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale University.

Bill Dickie

President and CEO

Bill Dickie joins APC after serving as Co-founder, President, CEO and Director of Atreus Pharmaceuticals, a radiopharmaceutical development company in Phase II clinical trials with a medical imaging product licensed from Stanford University. Under Bill’s leadership, Atreus raised $1 million in seed capital and negotiated a $6 million strategic investment, followed by a full acquisition by Advanced Accelerator Applications International, currently a Novartis company. Previously Bill served as President, CEO and Director of Liponex Inc., (TSX:LPX) a Phase 2 company developing a novel cardiovascular drug based on technology licensed from the University of Ottawa Heart Institute. During his time as CEO, Liponex raised $10.5 Million in an IPO. Bill also spent over 25 years in management and executive roles with MDS Nordion, a large Canadian health care company. Bill’s extensive experience provides Advanced Proteome with the necessary guidance, leadership and expertise during this next, important phase of its development. Mr Dickie holds a Bachelor of Commerce degree from Carleton University and a Masters of Business Administration degree from York University.

Kenneth C. Phillippe, B. Comm, CA

Kenneth C. Phillippe, B. Comm, CA

Chief Financial Officer

Mr. Phillippe is a Chartered Accountant with over 25 years’ experience working with public companies in the capacities of director, officer, financial advisor or consultant. Mr. Phillippe obtained a Bachelor of Commerce degree from the University of British Columbia in 1976. He articled with Thorne Riddell (now KPMG) and in1982 established his own accounting practice. During the period from February, 2000 to 2008, Mr. Phillippe held several high level Executive positions including director, officer, and chair of the audit committee of Urodynamix Technologies Ltd. (TSX – (URO.V))., CFO of Columbia Goldfields Ltd. (TSX – (GOL.TO) / OTCBB –(CGDF)), as Secretary, Treasurer, CFO and Principal Accounting Officer of Amazon Goldsands Ltd.(OTCBB – (AZNG)), as well as Constitution Mining Corp (OTCC – (CMIN)). Since 2006, Mr. Phillippe has served as Chief Financial Officer of Exchequer Resource Corp. (TSX/NEX – (EXQ.H)) as well as Chief Financial Officer and Secretary of Bold Ventures Inc. (TSX – (BOL.V)).

Our Scientific Advisory Board

Dr. Aditya Bardia

Attending Physician at Massachusetts General Hospital Cancer Center (MGHCC), Harvard Medical School, Boston

Dr. Bardia is a Director of the Precision Oncology Program at the MGH Center for Breast Cancer and active in areas which span the integration of precision diagnostics and precision therapeutics for significantly improving the outcomes of patients afflicted with breast cancer. He has been the principal investigator of several clinical trials related to novel therapies in breast cancer, including antibody-drug conjugates such as sacituzumab govitecan (IMMU-132) that was given breakthrough designation status by the FDA in 2016. Dr. Bardia has been the recipient of numerous awards as well as being co-leader of the Molecular and Precision tumor board at MGHCC, and an editorial board member of the American Society of Clinical Oncology (ASCO), Tumor Board.

Dr. Greg Thurber

Faculty of Chemical Engineering and Biomedical Engineering at the University of Michigan.

Dr. Thurber’s work involves applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents and developing an understanding of the critical factors that govern the distribution of agents, such as antibody-drug conjugates, in cells and tissues, to optimize their efficacies. An important point of focus is the matter of compatibility among antibody, linker, and toxin that comprise an ADC, which is central to the clinical success of this agent. Dr. Thurber, who has been a member of the Junior Faculty, Harvard Medical School/Massachusetts General Hospital, in the Radiology Department, has received several awards and is the recipient of a National Science Foundation CAREER award.

Dr. Paul Wender

Francis W. Bergstrom Professor of Chemistry and Professor, by courtesy, of Chemical and Systems Biology at Stanford University

Paul Wender received his B.S. degree from Wilkes University and his Ph.D. in chemistry from Yale University. He was an NIH Postdoctoral Fellow at Columbia University. He served on the faculty at Harvard University and joined the faculty at Stanford University where he is the Francis W. Bergstrom Professor of Chemistry and holds a courtesy appointment in the Department of Chemical and Systems Biology. Professor Wender’s research has been recognized with numerous awards including recently the Tetrahedron Prize, Prelog Medal (Swiss Federal Institute of Technology), Arthur Cope Award (American Chemical Society), Cohen Award for Excellence in Medicinal Chemistry (Israel Chemical Society), and Research Award of the German Bioactives and Biotechnology Leibniz Allaince. He has also been recognized with several teaching awards including the Hoagland Prize, Bing Teaching Award, and the Dean’s Teaching Award. He is an elected member of the US National Academy of Sciences, a foreign member of the Royal Spanish Academy of Sciences, and a fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences.

Our Board

Dr. Allen (Alexander) Krantz

Dr. Allen (Alexander) Krantz

Director

Allen Krantz has had an extensive career in academia and industry. From 1968 to 1980, he was a member of the Faculty of Chemistry at Stony Brook University, holding appointments in both the Department of Chemistry, and the Department of Pharmacological Sciences in the University’s Medical School. From 1981 to 1994, Dr. Krantz was Director, and then Vice-President of Research at Syntex Research Canada and held Adjunct Professorships during this period at the Universities of Toronto and Guelph while holding the title of Distinguished Scientist at the Corporation… From 1994 to 1997, Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique of the European office in France during the same period. Dr. Krantz was responsible for transforming the company’s program to a practical focal point on human serum albumin as a carrier of drugs. He is also a Founder, and served as the inaugural President of Pharmena North America Incorporated, a privately held, biotechnology company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale University.

Bill Dickie

Director

Bill Dickie joins APC after serving as Co-founder, President, CEO and Director of Atreus Pharmaceuticals, a radiopharmaceutical development company in Phase II clinical trials with a medical imaging product licensed from Stanford University. Under Bill’s leadership, Atreus raised $1 million in seed capital and negotiated a $6 million strategic investment, followed by a full acquisition by Advanced Accelerator Applications International, currently a Novartis company. Previously Bill served as President, CEO and Director of Liponex Inc., (TSX:LPX) a Phase 2 company developing a novel cardiovascular drug based on technology licensed from the University of Ottawa Heart Institute. During his time as CEO, Liponex raised $10.5 Million in an IPO. Bill also spent over 25 years in management and executive roles with MDS Nordion, a large Canadian health care company. Bill’s extensive experience provides Advanced Proteome with the necessary guidance, leadership and expertise during this next, important phase of its development. Mr Dickie holds a Bachelor of Commerce degree from Carleton University and a Masters of Business Administration degree from York University.

Dr. John Garrett

Director

Dr. Garrett is a Principal of John Garrett & Partners with a practice focusing on early stage US and international biomedical companies as well as corporate initiatives in the domains of software, and communication companies. Since 2004, Dr. Garrett has led five startup companies in CEO/COO positions, including initiatives with partners emanating from Harvard University and Roswell Park Cancer Center.  Currently, he is co-CEO of Glycosyn, Inc., centered on treating/curing common childhood diseases, and the Executive Director of Glycosyn Health Initiatives, devoted to bringing life-saving treatments to children in the developing world.

Paul Woodward

Director

Paul Woodward is currently President of Conation Capital Corp., and has been a frequent investor in early stage private companies. Paul is a former investment banker with over 30 years of experience in venture markets.